eligibility_summary
Adults ≥18 with ECOG 0–1, life expectancy >3 mo, histologically confirmed B‑cell NHL, relapsed/refractory after ≥1 prior line or treatment‑naïve, ≥1 measurable lesion (nodal >1.5 cm or extranodal >1.0 cm). Exclude: recent auto‑SCT (<12 wks), prior allo‑SCT, CAR‑T (<12 wks), major surgery/trauma (<4 wks), anti‑tumor therapy (<2 wks), CNS involvement, active HBV/HCV, immunodeficiency (incl. HIV/TB), active infection or fever >38.5°C, severe CV disease.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: NCT06104553 (Phase Ib/II). Intervention: SHR-A1912 plus R‑Chemo (rituximab + chemotherapy). Drug types/mechanisms: • Rituximab: anti‑CD20 monoclonal antibody, depletes B cells via ADCC, CDC, and apoptosis. • Chemotherapy: cytotoxic agents (specific drugs not listed) that damage DNA and/or disrupt mitosis in rapidly dividing lymphoma cells. • SHR-A1912: investigational anticancer agent from Hengrui, mechanism/target not specified in the registry. Targets/cellular pathways: • Malignant CD20+ B cells (via rituximab). • Immune effector pathways (NK cell–mediated ADCC, complement activation). • Proliferation/DNA replication and mitotic pathways in lymphoma cells (via chemotherapy). Population: adults with B‑cell NHL (both previously untreated and relapsed/refractory). Purpose: assess safety, PK, and preliminary antitumor activity of the combination.